In an adult patient with supra‑refractory status epilepticus who has no hepatic failure and is not pregnant, which antiseizure medication—lamotrigine, lacosamide, or valproate—should be swapped for cenobamate?

Cenobamate Should Not Replace Any of These Medications in Supra-Refractory Status Epilepticus

In supra-refractory status epilepticus (SRSE), cenobamate should not be used to swap out lamotrigine, lacosamide, or valproate—instead, it should be added as adjunctive therapy while maintaining established SRSE treatments, particularly valproate and anesthetic agents. The evidence base for cenobamate in SRSE consists only of small case series with delayed initiation (median 13-103 days after SE onset), making it unsuitable as a replacement strategy in the acute management phase 1, 2.

Why This Recommendation

The Evidence Landscape for SRSE Management

The 2014 ACEP guidelines establish the standard treatment algorithm for refractory status epilepticus 3:

• Level B recommendation: Valproate, phenytoin, or fosphenytoin should be administered after benzodiazepine failure
• Level C recommendation: Levetiracetam, propofol, or barbiturates may be used in refractory cases
• Valproate demonstrated 79% seizure control as second-line therapy versus only 25% for phenytoin, with superior safety (no hypotension versus 12% with phenytoin) 3

Lacosamide is mentioned only briefly in future directions as potentially useful but requiring more study 3. It lacks the robust evidence base of valproate in status epilepticus.

Cenobamate's Limited Role in SRSE

The cenobamate evidence in SRSE is extremely limited:

• Only 3 reported cases with median initiation at 27 days post-SE onset (range 13-103 days) 1
• Two additional cases with slow uptitration to avoid DRESS syndrome 2
• Median dose at SRSE cessation was only 25 mg/day (range 12.5-50 mg/day), far below therapeutic targets 1
• Two of three patients died in the largest case series 1

Critical limitation: Cenobamate requires slow titration over weeks to months to minimize hypersensitivity reactions 2, 4. This titration schedule is fundamentally incompatible with the time-sensitive nature of SRSE, where mortality increases with each passing day.

The Specific Medications in Question

Valproate has the strongest evidence:

• Class II studies showing 88% seizure cessation within 20 minutes 3
• Can be given rapidly (20-30 mg/kg at 40 mg/min) 3
• Recommended by Neurocritical Care Society for both emergent and refractory SE 3
• Should never be removed in SRSE given its proven efficacy and rapid action 5

Lacosamide has minimal evidence in SE:

• Mentioned only as needing further study 3
• Not included in guideline recommendations 3
• However, it has a favorable safety profile and can be loaded quickly
• If already on board, maintain it—but it's not a primary SRSE agent

Lamotrigine is not mentioned in any SRSE guidelines:

• Requires extremely slow titration (weeks) due to Stevens-Johnson syndrome risk
• No IV formulation for acute use
• Has no role in acute SRSE management
• If a patient is on lamotrigine chronically, maintain it to prevent withdrawal seizures, but don't expect it to control SRSE

The Correct Approach

What to Actually Do in SRSE

1. Maintain valproate at therapeutic doses (20-30 mg/kg loading, then 1-2 mg/kg/hour infusion) 3

2. Escalate to anesthetic agents per guidelines:

   • Midazolam, propofol, or pentobarbital 3
   • Propofol: 2 mg/kg bolus, 5 mg/kg/hour infusion 3
   • Pentobarbital: 13 mg/kg bolus, 2-3 mg/kg/hour infusion (92% efficacy) 3

3. Consider cenobamate as adjunctive therapy only after:

   • SRSE is controlled with anesthetics
   • Patient is stable enough for slow titration
   • Goal is long-term seizure control, not acute SRSE termination 1, 2

4. If lacosamide is already on board, maintain it—no evidence supports removing it

5. Lamotrigine has no acute role—maintain only if patient was on it chronically to prevent withdrawal

Common Pitfalls to Avoid

• Do not delay anesthetic therapy while attempting cenobamate titration—mortality increases with SRSE duration
• Do not remove valproate thinking cenobamate will replace it—valproate has proven rapid efficacy; cenobamate does not 3, 1
• Do not rapid-load cenobamate—this risks severe DRESS syndrome, which has been fatal 2, 4
• Do not confuse focal epilepsy data with SRSE management—cenobamate's impressive 50-61% responder rates are in chronic focal epilepsy, not acute SE 6, 7

The Reality of Cenobamate in SRSE

Cenobamate shows promise as an add-on agent for long-term management after SRSE resolution 1, 2. The case series suggest it may help prevent SE recurrence when titrated slowly over weeks in stabilized patients. However, its pharmacokinetic profile (requiring weeks of titration, risk of DRESS, lack of IV formulation) makes it fundamentally unsuitable for acute SRSE management where hours matter for survival 8, 9.

The question asks which medication to swap—the answer is none of them. Maintain valproate for its proven rapid efficacy, escalate to anesthetics per guidelines, and consider adding cenobamate only after stabilization for long-term seizure control.